Advertisement
U.S. markets closed

  • S&P Futures

    4,586.00
    +11.00 (+0.24%)
     

  • Dow Futures

    36,238.00
    +49.00 (+0.14%)
     

  • Nasdaq Futures

    15,973.00
    +64.25 (+0.40%)
     

  • Russell 2000 Futures

    1,866.70
    +6.90 (+0.37%)
     

  • Crude Oil

    72.36
    +0.04 (+0.06%)
     

  • Gold

    2,038.70
    +2.40 (+0.12%)
     

  • Silver

    24.58
    +0.03 (+0.14%)
     

  • EUR/USD

    1.0797
    -0.0006 (-0.05%)
     

  • 10-Yr Bond

    4.1710
    -0.1170 (-2.73%)
     

  • Vix

    12.85
    -0.23 (-1.76%)
     

  • GBP/USD

    1.2604
    +0.0012 (+0.09%)
     

  • USD/JPY

    147.2190
    +0.1110 (+0.08%)
     

  • Bitcoin USD

    44,075.04
    +2,373.15 (+5.69%)
     

  • CMC Crypto 200

    901.21
    +40.67 (+4.73%)
     

  • FTSE 100

    7,489.84
    -23.12 (-0.31%)
     

  • Nikkei 225

    33,221.83
    +446.01 (+1.36%)
     

Sunesis: Q4 Earnings Snapshot

Associated Press Finance
·1 min read

CARDIFF, Calif. (AP) — CARDIFF, Calif. (AP) — Viracta Therapeutics, Inc. (VIRX) on Monday reported a loss of $10.3 million in its fourth quarter.

On a per-share basis, the Cardiff, California-based company said it had a loss of 27 cents.

The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 40 cents per share.

For the year, the company reported a loss of $49.2 million, or $1.30 per share.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on VIRX at https://www.zacks.com/ap/VIRX

Advertisement